Emergent Biosolutions (EBS) Issues Q3 Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $5.90 -5.6%
Financial Fact:
Net income (loss) attributable to Emergent BioSolutions Inc.: 21.34M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Net income (loss) attributable to Emergent BioSolutions Inc.: 21.34M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q3 EPS of $0.04, $0.06 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $58.8 million versus the consensus estimate of $63.59 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Emergent BioSolutions (EBS) Misses Q3 EPS by 23c
- Lemaitre Vascular (LMAT) Misses Q3 EPS by 4c ; Offers Guidance
- Compass Diversified (CODI) Misses Q3 EPS by 2c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
